Clinical Trial Search

Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants

Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months

Primary: Number of Participants With Progressive Disease, — 2 Participants

Primary: Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the…

Primary: Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy — 49 percent of patients

Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001

Primary: Objective Response Rate — 1; 15 Participants

Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001

Primary: Overall Survival (OS) — 9.38; 14.7 Months

Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…

Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants

Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months

Primary: Median Overall Survival (OS) — 42 months

Primary: One Year Survival Rate — 0.502 proportion of patients

Primary: Six Month Survival Rate — 25; 67; 33 percentage of patients

Primary: Conversion Rate of Inoperable to Operable

Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants

Primary: Overall Survival — 24.8 Months

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. — 0; 12; 12; 4 Participants

Primary: Number of Participants With Resectability Rate — 15 Participants

Primary: MK-0646 Maximum Tolerable Dose — 0; 0; 0; 2 participants

Primary: Progression-free Survival — 5.7 months

Primary: The Percentage of Patients That Underwent an R0 Resection — 52 percentage of patients

Primary: Overall Survival (OS) — 210; 171 Days — p=0.1026

Primary: Frequency of R0 Resection — 11; 2 Participants

Primary: Surgical Exploration — 4; 6; 9 Participants

Primary: To Determine the Rate of (Grade 2 or Greater) Gastrointestinal Toxicity Attributable to Gemcitabine and Fractionated SBRT at One Year. — 5 Number of toxicities.

Primary: Response Rate — .125 proportion of participants

Primary: Progression-free Survival (PFS) — 6.5; 8.4 months